| Identification | Back Directory | [Name]
(R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic acid | [CAS]
1072833-77-2 | [Synonyms]
MLN2238
CS-1976
IxazoMib
Ixazomib-d7
ixazomib(MLN2238)
MLN2238(iaxzomib)
MLN2238(Ixazomib)
Ixazomib (MLN-9708)
Ixazomib (10mM in DMSO)
MLN2238;MLN 2238;MLN-2238
IXAZOMIB;MLN 2238;MLN-2238
1-(2-(2,5-dichlorobenzamido)acetamido)-
3-methylbutylboronic acid
(R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic acid
(R)-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbuyl)boronic acid
(1R)-1-{2-[(2,5-dichlorophenyl)formamido]acetamido}-3-methylbutyl]boronic acid
B-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid
Boronic acid, B-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-
Ixazomib-13C2,15NQ: What is
Ixazomib-13C2,15N Q: What is the CAS Number of
Ixazomib-13C2,15N
B-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid Ixazomib (MLN2238)
Ixazomib, 98%, a selective, potent, and reversible proteasome inhibitor, which inhibits the chymotrypsin-like proteolytic (5) site of the 20S proteasome with an IC50 of 3.4 nM (Ki of 0.93 nM) | [EINECS(EC#)]
810-246-8 | [Molecular Formula]
C14H19BCl2N2O4 | [MDL Number]
MFCD18251438 | [MOL File]
1072833-77-2.mol | [Molecular Weight]
361 |
| Chemical Properties | Back Directory | [Melting point ]
>142°C (subl.) | [density ]
1.306 | [storage temp. ]
-20°C Freezer | [solubility ]
DMSO (Sparingly), Methanol (Slightly) | [form ]
Solid | [pka]
9.67±0.43(Predicted) | [color ]
White to Pale Yellow |
| Hazard Information | Back Directory | [Uses]
Ixazomib is a proteasome inhibitor that acts by preventing cell growth in solid tumours. It is an anticancer agent that is used to treat patients with multiple myeloma and is potentially neurotoxic. | [Definition]
ChEBI: A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixa
omib citrate, it is used in combination therapy for treatment of multiple myeloma. | [in vivo]
Ixazomib (MLN2238) shows antitumor activity in the CWR22 xenograft model. The antitumor effects of Ixazomib (MLN2238) dosed at 14 mg/kg i.v. or 7 mg/kg i.v. are compared with Bortezomib dosed at 0.8 mg/kg i.v. or 0.4 mg/kg i.v. on a twice weekly regimen. The high dose for both Ixazomib (MLN2238) and Bortezomib (HY-10227) shows similar antitumor activity in this model (T/C=0.36 and 0.44, respectively). However, Ixazomib (MLN2238) (7 mg/kg) shows greater efficacy at a 0.5 MTD dose compared with a 0.5 MTD dose of Bortezomib (0.4 mg/kg; T/C=0.49 compared with T/C=0.79, respectively) Ixazomib (MLN2238) shows time-dependent reversible proteasome inhibition; however, the proteasome dissociation half-life (t1/2) for Ixazomib (MLN2238) is determined to be 18 minutes[1]. | [target]
chymotrypsin-like proteolytic (β5) site of the 20S proteasome |
|
|